Dompe sells ovarian cancer treatment to AAA
Currently under preclinical development, FabOvar is intended as an treatment for ovarian carcinoma. AAA CEO Stefano Buono said in previous studies FabOvar is an evolution of a previous
Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy.